There are new and pending antibiotics that are broad-spectrum and highly effective, with favorable safety profiles, but that doesn’t mean infectious disease specialists can breathe easy.
“We have new gram-negative antimicrobials in several different areas of importance. However, now we are running into a new problem, which is that companies are struggling in the marketplace due to a reluctance to use some of their medications,” said Jason Gallagher, PharmD,